Protagonist Therapeutics Announces Presentation of Icotrokinra Phase 2b Trial Results at United European Gastroenterology Week 2025
Protagonist Therapeutics, Inc. announced that results from the Phase 2b ANTHEM-UC study of icotrokinra for ulcerative colitis will be presented at the United European Gastroenterology Week 2025 in Berlin on October 7, 2025. The presentation will cover Week 12 results from this randomized, double-blind, placebo-controlled study, focusing on icotrokinra's effects on patients with moderately to severely active ulcerative colitis. Dr. Maria Abreu from Cedars-Sinai Medical Center will deliver the presentation.
Protagonist Therapeutics, Inc. has announced that data from the Phase 2b ANTHEM-UC study involving the drug icotrokinra for the treatment of ulcerative colitis will be the subject of an oral presentation at the upcoming United European Gastroenterology Week 2025 in Berlin, Germany. The presentation, scheduled for October 7, 2025, will focus on the Week 12 results of the trial, which is a randomized, double-blind, placebo-controlled, dose-ranging study. The study evaluates icotrokinra, a targeted oral peptide that selectively blocks IL-23 receptor activation, in patients with moderately to severely active ulcerative colitis. The presentation will be delivered by Dr. Maria Abreu from Cedars-Sinai Medical Center, and abstracts are currently available on the UEGW website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073229) on September 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
